Azytromycyna: interakcje

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

• Cardiovascular Death: Some observational studies have shown an approximately two-fold increased short-term potential risk of acute cardiovascular death in adults exposed to azithromycin relative to other antibacterial drugs, including amoxicillin. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

• Cardiovascular Death: Some observational studies have shown an approximately two-fold increased short-term potential risk of acute cardiovascular death in adults exposed to azithromycin relative to other antibacterial drugs, including amoxicillin. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

…bradyarrhythmias or uncompensated heart failure • patients on drugs known to prolong the QT interval • patients with ongoing proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, and in patients receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

WARNING: PERIPHERAL ISCHEMIA FOLLOWING COADMINISTRATION WITH POTENT CYP3A4 INHIBITORS Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of dihydroergotamine with potent CYP3A4 inhibitors including protease inhibitors and macrolide antibiotics. (etykieta leku Dihydroergotamina, Ostrzeżenie w ramce)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

Concomitant use of COMPLERA with drugs with a known risk to prolong the QTc interval of the electrocardiogram may increase the risk of Torsade de Pointes. (etykieta leku Emtrycytabina + rylpiwiryna + tenofowir, Ostrzeżenia i środki ostrożności)

WARNING Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of ergotamine tartrate and caffeine tablets with potent CYP 3A4 inhibitors including protease inhibitors and macrolide antibiotics. (etykieta leku Ergotamina + kofeina, Ostrzeżenie w ramce)

• Patients with known hypersensitivity to azithromycin, erythromycin, any macrolide, or ketolide antibacterial drug. (etykieta leku Azytromycyna, Przeciwwskazania)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

VYTORIN is contraindicated in the following conditions: Concomitant use of strong CYP3A4 inhibitors (select azole anti-fungals, macrolide antibiotics, anti-viral medications, and nefazodone) [see Drug Interactions (7.1) ] . (etykieta leku Ezetymib + symwastatyna, Przeciwwskazania)

Drugs that Prolong the QT Interval : Avoid concomitant use. (etykieta leku Fenobarbital, Interakcje z innymi lekami)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

Avoid co-administration of CONTEPO with drugs known to prolong the QT interval. (etykieta leku Fosfomycyna, Interakcje z innymi lekami)

(See DOSAGE and ADMINISTRATION. ) Because of the risk of QT prolongation and the potential for torsades de pointes, the use of FOSCAVIR should be avoided in combination with agents known to prolong the QT interval including Class IA (e.g., quinidine or procainamide) or Class III (e.g., dofetilide, amiodarone, sotalol) antiarrhythmic agents, phenothiazines, tricyclic… (etykieta leku Foskarnet, Interakcje z innymi lekami)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (etykieta leku Iwabradyna, Ostrzeżenia i środki ostrożności)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

Avoid use in patients with congenital long QT syndrome, those with hypokalemia, and with other drugs that prolong the QT interval. (etykieta leku Lopinawir + rytonawir, Ostrzeżenia i środki ostrożności)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

Examples diazepam, alprazolam, alcohol Drugs that Prolong QTc Interval Clinical Impact The concomitant use of other drugs which prolong the QTc interval with REMERON/REMERONSolTab, increase the risk of QT prolongation and/or ventricular arrhythmias (e.g., Torsades de Pointes). (etykieta leku Mirtazapina, Interakcje z innymi lekami)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

Avoid coadministration of oxaliplatin injection with medicinal products with a known potential to prolong the QT interval. (etykieta leku Oksaliplatyna, Interakcje z innymi lekami)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (etykieta leku Pazopanib, Interakcje z innymi lekami)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

• Avoid use with other antiarrhythmic agents or drugs that prolong the QT interval. (etykieta leku Propafenon, Ostrzeżenia i środki ostrożności)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

Macrolide or ketolide antibiotics: azithromycin clarithromycin erythromycin ↑ rilpivirine ↔ azithromycin ↔ clarithromycin ↔ erythromycin Macrolides are expected to increase concentrations of rilpivirine and are associated with a risk of Torsade de Pointes [Warnings and Precautions (5.4)]. (etykieta leku Rylpiwiryna, Interakcje z innymi lekami)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

Avoid the concomitant use of drugs known to prolong the QTc interval. (etykieta leku Sertralina, Interakcje z innymi lekami)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

ZOCOR is contraindicated in the following conditions: Concomitant use of strong CYP3A4 inhibitors (select azole anti-fungals, macrolide antibiotics, anti-viral medications, and nefazodone) [see Drug Interactions (7.1) ] . (etykieta leku Symwastatyna, Przeciwwskazania)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

Avoid concomitant use of VEPPANU with strong CYP3A inhibitors or drugs known to prolong the QTc interval. (etykieta leku Vepdegestrant, Ostrzeżenia i środki ostrożności)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

…bradyarrhythmias or uncompensated heart failure • patients on drugs known to prolong the QT interval • patients with ongoing proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, and in patients receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

Amlodipine and atorvastatin tablets dosage modifications are recommended for patients taking certain anti-viral, azole antifungals, or macrolide antibiotic medications [see Dosage and Administration (2) ] . (etykieta leku Amlodypina + atorwastatyna, Ostrzeżenia i środki ostrożności)

Prothrombin times should be carefully monitored while patients are receiving azithromycin and oral anticoagulants concomitantly. (etykieta leku Azytromycyna, Interakcje z innymi lekami)

MAO inhibitors, tricyclic antidepressants and drugs that prolong the QTc interval may potentiate effect on the cardiovascular system. (etykieta leku Arformoterol, Interakcje z innymi lekami)

Prothrombin times should be carefully monitored while patients are receiving azithromycin and oral anticoagulants concomitantly. (etykieta leku Azytromycyna, Interakcje z innymi lekami)

Macrolide antibiotics: clarithromycin ↑ clarithromycin ↓ 14-OH clarithromycin ↑ atazanavir Increased concentrations of clarithromycin may cause QTc prolongations; therefore, a dose reduction of clarithromycin by 50% should be considered when it is coadministered with REYATAZ. (etykieta leku Atazanawir, Interakcje z innymi lekami)

LIPITOR dosage modifications are recommended for patients taking certain anti-viral, azole antifungals, or macrolide antibiotic medications [see Dosage and Administration (2.5) ] . (etykieta leku Atorwastatyna, Ostrzeżenia i środki ostrożności)

Prothrombin times should be carefully monitored while patients are receiving azithromycin and oral anticoagulants concomitantly. (etykieta leku Azytromycyna, Interakcje z innymi lekami)

The risk of combining buprenorphine with other QT-prolonging agents is not known. (etykieta leku Buprenorfina, Ostrzeżenia i środki ostrożności)

The risk of combining buprenorphine with other QT-prolonging agents is not known. (etykieta leku Buprenorfina + nalokson, Ostrzeżenia i środki ostrożności)

Cytochrome P450 3A4 Interaction The concomitant use of BUTALBITAL, ASPIRIN, CAFFEINE and CODEINE PHOSPHATE with all cytochrome P450 3A4 inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir) or discontinuation of a cytochrome P450 3A4 inducer such as rifampin, carbamazepine,… (etykieta leku Butalbital + kwas acetylosalicylowy + kofeina + kodeina, Ostrzeżenia i środki ostrożności)

• Cytochrome P450 3A4 Interaction The concomitant use of Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules with all cytochrome P450 3A4 inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir) or discontinuation of a cytochrome P450 3A4 inducer such… (etykieta leku Butalbital + paracetamol + kofeina + kodeina, Ostrzeżenia i środki ostrożności)

Drugs That Increase Cyclosporine Concentrations Calcium Channel Blockers Antifungals Antibiotics Glucocorticoids Other Drugs diltiazem fluconazole azithromycin methylprednisolone Allopurinol nicardipine itraconazole clarithromycin Amiodarone verapamil ketoconazole erythromycin Bromocriptine voriconazole quinupristin/ dalfopristin colchicine danazol imatinib metoclopramide… (etykieta leku Cyklosporyna, Interakcje z innymi lekami)

QT Interval Prolongation and V entricular A rr h ythmia Decreases in serum calcium can also prolong the QT interval, potentially resulting in ventricular arrhythmia. (etykieta leku Cynakalcet, Ostrzeżenia i środki ostrożności)

Prothrombin times should be carefully monitored while patients are receiving azithromycin and oral anticoagulants concomitantly. (etykieta leku Azytromycyna, Interakcje z innymi lekami)

Carefully monitor cardiac rhythm when administering SUPRANE to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (etykieta leku Desfluran, Ostrzeżenia i środki ostrożności)

Until further data are developed regarding drug interactions when digoxin, colchicine or phenytoin are used with azithromycin careful monitoring of patients is advised. (etykieta leku Azytromycyna, Interakcje z innymi lekami)

…bradyarrhythmias or uncompensated heart failure • patients on drugs known to prolong the QT interval • patients with ongoing proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, and in patients receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

Concomitant administration of moderate or strong CYP3A4 inhibitors such as azole antifungals (e.g., ketoconazole, itraconazole, voriconazole, fluconazole), verapamil, macrolides (e.g., clarithromycin, erythromycin), diltiazem, and grapefruit juice can increase the plasma concentrations of the estrogen or the progestin or both. (etykieta leku Drospirenon + etynyloestradiol, Interakcje z innymi lekami)

Prothrombin times should be carefully monitored while patients are receiving azithromycin and oral anticoagulants concomitantly. (etykieta leku Azytromycyna, Interakcje z innymi lekami)

QT Prolonging Drugs There is limited information available on the potential for a pharmacodynamic interaction between efavirenz and drugs that prolong the QTc interval. (etykieta leku Efawirenz, Interakcje z innymi lekami)

QT Prolonging Drugs There is limited information available on the potential for a pharmacodynamic interaction between EFV and drugs that prolong the QTc interval. (etykieta leku Efawirenz + lamiwudyna + tenofowir, Interakcje z innymi lekami)

Prothrombin times should be carefully monitored while patients are receiving azithromycin and oral anticoagulants concomitantly. (etykieta leku Azytromycyna, Interakcje z innymi lekami)

QT Prolongation: Monitor for prolonged QT intervals in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, and electrolyte abnormalities. (etykieta leku Erybulina, Ostrzeżenia i środki ostrożności)

…bradyarrhythmias or uncompensated heart failure • patients on drugs known to prolong the QT interval • patients with ongoing proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, and in patients receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

…Systemic Exposure of COCs (enzyme inhibitors): Concomitant administration of moderate or strong CYP3A4 inhibitors like azole antifungals (for example, ketoconazole, itraconazole, voriconazole, fluconazole), verapamil, macrolides (for example, clarithromycin, erythromycin), diltiazem, and grapefruit increase the serum concentrations of both estradiol and dienogest. (etykieta leku Estradiol + dienogest, Interakcje z innymi lekami)

Alternatives to clarithromycin, such as azithromycin, should be considered for the treatment of MAC. (etykieta leku Etrawiryna, Interakcje z innymi lekami)

Risks of Concomitant Use or Discontinuation of Cytochrome P450 3A4 Inhibitors and Inducers Concomitant use of Fentanyl Citrate Injection with a CYP3A4 inhibitor, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may increase plasma concentrations of fentanyl and prolong… (etykieta leku Fentanyl, Ostrzeżenia i środki ostrożności)

Until further data are developed regarding drug interactions when digoxin, colchicine or phenytoin are used with azithromycin careful monitoring of patients is advised. (etykieta leku Azytromycyna, Interakcje z innymi lekami)

Prothrombin times should be carefully monitored while patients are receiving azithromycin and oral anticoagulants concomitantly. (etykieta leku Azytromycyna, Interakcje z innymi lekami)

…Antidepressants, QTc Prolonging Drugs Formoterol, as with other beta 2 -agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval because the effect of adrenergic agonists on the cardiovascular system may be potentiated by these agents. (etykieta leku Formoterol, Interakcje z innymi lekami)

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (etykieta leku Goserelina, Ostrzeżenia i środki ostrożności)

Prothrombin times should be carefully monitored while patients are receiving azithromycin and oral anticoagulants concomitantly. (etykieta leku Azytromycyna, Interakcje z innymi lekami)

…www.fda.gov/OpioidAnalgesicREMSBlueprint 5.6 Risks of Concomitant Use or Discontinuation of Cytochrome P450 3A4 Inhibitors and Inducers Concomitant use of HYSINGLA ER with a CYP3A4 inhibitor, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may increase plasma concentrations of hydrocodone… (etykieta leku Hydrokodon, Ostrzeżenia i środki ostrożności)

…Concomitant Use or Discontinuation of Cytochrome P450 3A4 Inhibitors and Inducers Concomitant use of Hydrocodone Polistirex and Chlorpheniramine Polistirex with a CYP3A4 inhibitor, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may increase plasma concentrations of hydrocodone… (etykieta leku Hydrokodon + chlorfenamina, Ostrzeżenia i środki ostrożności)

…Concomitant Use or Discontinuation of Cytochrome P450 3A4 Inhibitors and Inducers Concomitant use of hydrocodone bitartrate and homatropine methylbromide with a CYP3A4 inhibitor, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may increase plasma concentrations of hydrocodone… (etykieta leku Hydrokodon + homatropina, Ostrzeżenia i środki ostrożności)

…Concomitant Use or Discontinuation of Cytochrome P450 3A4 Inhibitors and Inducers Concomitant use of Hydrocodone Bitartrate and Ibuprofen Tablets with a CYP3A4 inhibitor, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may increase plasma concentrations of hydrocodone… (etykieta leku Hydrokodon + ibuprofen, Ostrzeżenia)

…Concomitant Use or Discontinuation of Cytochrome P450 3A4 Inhibitors and Inducers Concomitant use of hydrocodone bitartrate and acetaminophen tablets with a CYP3A4 inhibitor, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may increase plasma concentrations of hydrocodone… (etykieta leku Hydrokodon + paracetamol, Ostrzeżenia)

Monitor QT interval when administering FORANE to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (etykieta leku Izofluran, Ostrzeżenia i środki ostrożności)

Cytochrome P450 3A4 Interaction: The concomitant use of Codeine Sulfate Tablets with all cytochrome P450 3A4 inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir) or discontinuation of a cytochrome P450 3A4 inducer such as rifampin, carbamazepine, and phenytoin,… (etykieta leku Kodeina, Ostrzeżenia i środki ostrożności)

Until further data are developed regarding drug interactions when digoxin, colchicine or phenytoin are used with azithromycin careful monitoring of patients is advised. (etykieta leku Azytromycyna, Interakcje z innymi lekami)

TYKERB may prolong the QT interval in some patients. (etykieta leku Lapatynib, Ostrzeżenia i środki ostrożności)

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (etykieta leku Leuprorelina, Ostrzeżenia i środki ostrożności)

…bradyarrhythmias or uncompensated heart failure • patients on drugs known to prolong the QT interval • patients with ongoing proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, and in patients receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

…bradyarrhythmias or uncompensated heart failure • patients on drugs known to prolong the QT interval • patients with ongoing proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, and in patients receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (etykieta leku Lofeksydyna, Ostrzeżenia i środki ostrożności)

Other Drugs that Prolong the QTc Interval Coadministration of other drugs known to alter cardiac conduction (e.g., anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H 1 -blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval. (etykieta leku Meflochina, Interakcje z innymi lekami)

…bradyarrhythmias or uncompensated heart failure • patients on drugs known to prolong the QT interval • patients with ongoing proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, and in patients receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

Drugs that Prolong the QT Interval QT prolongation has been reported, particularly when metronidazole was administered with drugs with the potential for prolonging the QT interval. (etykieta leku Metronidazol, Interakcje z innymi lekami)

Antibiotics : Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance (see PRECAUTIONS: Drug Interactions, Hepatic Enzyme Inhibitors ). (etykieta leku Metyloprednizolon, Interakcje z innymi lekami)

There is little or no experience with high exposure, concomitant dosing with other QT-prolonging drugs, or potassium channel variants resulting in a long QT interval. [See Warnings & Precautions ( 5.6 )] To minimize risk, the lowest effective dose should always be used. (etykieta leku Mifepryston, Ostrzeżenia i środki ostrożności)

Alternatives to clarithromycin, such as azithromycin, should be considered. (etykieta leku Newirapina, Interakcje z innymi lekami)

CYP3A Inhibitors CYP3A inhibitors such as ketoconazole, fluconazole, itraconazole, clarithromycin, erythromycin (Azithromycin, although structurally related to the class of macrolide antibiotic is void of clinically relevant CYP3A4 inhibition), grapefruit, nefazodone, fluoxetine, saquinavir, indinavir, nelfinavir, and ritonavir may result in increased exposure… (etykieta leku Nifedypina, Interakcje z innymi lekami)

Possible Increased Risk of Hypotension with Strong CYP3A4 Inhibitors Concomitant use of strong inhibitors of CYP3A4, such as some macrolide antibiotics (e.g., clarithromycin, telithromycin), some HIV protease inhibitors (e.g., indinavir, nelfinavir, ritonavir, saquinavir), some HCV protease inhibitors (e.g., boceprevir, telaprevir), some azole antimycotics (e.g.,… (etykieta leku Nimodypina, Ostrzeżenia i środki ostrożności)

Risks of Concomitant Use or Discontinuation of Cytochrome P450 3A4 Inhibitors and Inducers Concomitant use of Oxycodone Hydrochloride Oral Solution with a CYP3A4 inhibitor, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may increase plasma concentrations of oxycodone… (etykieta leku Oksykodon, Ostrzeżenia i środki ostrożności)

Risks of Concomitant Use or Discontinuation of Cytochrome P450 3A4 Inhibitors and Inducers Concomitant use of oxycodone hydrochloride tablets with a CYP3A4 inhibitor, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may increase plasma concentrations of oxycodone and prolong… (etykieta leku Oksykodon + paracetamol, Ostrzeżenia i środki ostrożności)

Cytochrome P450 3A4 Interaction The concomitant use of acetaminophen and codeine phosphate tablets with all cytochrome P450 3A4 inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir) or discontinuation of a cytochrome P450 3A4 inducer such as rifampin, carbamazepine,… (etykieta leku Paracetamol + kodeina, Ostrzeżenia)

Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (etykieta leku Pasyreotyd, Interakcje z innymi lekami)

Risks of Concomitant Use or Discontinuation of Cytochrome P450 3A4 Inhibitors and Inducers Concomitant use of DEMEROL Injection with a CYP3A4 inhibitor, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), and protease inhibitors (e.g., ritonavir), may increase plasma concentrations of meperidine and prolong opioid… (etykieta leku Petydyna, Ostrzeżenia i środki ostrożności)

Anti-Arrhythmic Drugs, QT Prolonging Drugs, Drugs that may Decrease Heart Rate PONVORY has not been studied in patients taking QT prolonging drugs. (etykieta leku Ponesimod, Interakcje z innymi lekami)

Other macrolides (e.g., azithromycin) have the potential to increase pravastatin sodium exposures and increase the risk of myopathy and rhabdomyolysis when used concomintantly. (etykieta leku Prawastatyna, Interakcje z innymi lekami)

CYP 3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics): Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to an increased risk of corticosteroid side effects. (etykieta leku Prednizolon, Interakcje z innymi lekami)

CYP 3A4 Inhibitors (e.g., Ketoconazole, Macrolide Antibiotics) Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60% leading to increased risk of corticosteroid side effects. (etykieta leku Prednizon, Interakcje z innymi lekami)

Until further data are developed regarding drug interactions when digoxin, colchicine or phenytoin are used with azithromycin careful monitoring of patients is advised. (etykieta leku Azytromycyna, Interakcje z innymi lekami)

QT Interval Prolonging Drugs The pharmacodynamic interaction potential to prolong the QT interval of the electrocardiogram between Primaquine phosphate Tablets and other drugs that effect cardiac conduction is unknown. (etykieta leku Prymachina, Interakcje z innymi lekami)

QT Interval Prolongation The overall analysis of ECG data in pediatric patients indicates that the concomitant use of Rocuronium Bromide Injection with general anesthetic agents can prolong the QTc interval [see Clinical Studies ( 14.3 )]. (etykieta leku Rokuronium, Ostrzeżenia i środki ostrożności)

ND ↓ AUC by 27 – 40% Sulfamethoxazole-Trimethoprim 800/160 mg 300 mg once a day HIV-infected patients (12) ↔ ↓ AUC by 15–20% ANTI-MAC (Mycobacterium avium intracellulare complex) Azithromycin 500 mg once a day for 1 day, then 250 mg once a day for 9 days 300 mg once a day Healthy subjects (6) ↔ ↔ Clarithromycin 500 mg twice a day 300 mg once a day HIV-infected… (etykieta leku Ryfabutyna, Interakcje z innymi lekami)

Prothrombin times should be carefully monitored while patients are receiving azithromycin and oral anticoagulants concomitantly. (etykieta leku Azytromycyna, Interakcje z innymi lekami)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (etykieta leku Sewofluran, Ostrzeżenia)

Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (etykieta leku Sorafenib, Ostrzeżenia i środki ostrożności)

Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (etykieta leku Sunitynib, Interakcje z innymi lekami)

Antibiotics: Macrolide antibiotics have been reported to cause a significant decrease in corticosteroid clearance. (etykieta leku Triamcynolon, Interakcje z innymi lekami)

Macrolide Antibiotics Coadministration of erythromycin increased the maximum plasma concentration, decreased clearance and increased half-life of triazolam [see Drug Interactions (7.1) , Clinical Pharmacology (12.3) ] ; caution and consideration of appropriate triazolam dose reduction are recommended. (etykieta leku Triazolam, Ostrzeżenia i środki ostrożności)

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (etykieta leku Tryptorelina, Ostrzeżenia i środki ostrożności)

…like other beta 2 -agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval or within 2 weeks of discontinuation of such agents, because the effect of adrenergic agonists on the cardiovascular system may be potentiated by these agents. (etykieta leku Umeklidynium + wilanterol, Interakcje z innymi lekami)

• Warfarin: Use with azithromycin may increase coagulation times; monitor prothrombin time. (etykieta leku Azytromycyna, Interakcje z innymi lekami)

…bradyarrhythmias or uncompensated heart failure • patients on drugs known to prolong the QT interval • patients with ongoing proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, and in patients receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents. (etykieta leku Azytromycyna, Ostrzeżenia i środki ostrożności)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (etykieta leku Zasadowy cytrynian bizmutu + metronidazol + tetracyklina, Ostrzeżenia i środki ostrożności)

The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A: nefazodone, fluvoxamine, cimetidine, diltiazem, isoniazide, and some macrolide antibiotics. (etykieta leku Estazolam, Ostrzeżenia)

However, drug interactions have been observed with other macrolide products. (etykieta leku Azytromycyna, Interakcje z innymi lekami)

Antipyrine, Azithromycin, Cimetidine, Erythromycin, Ketoconazole, Theophylline, and Pseudoephedrine Pharmacokinetic interaction studies performed with racemic cetirizine demonstrated that cetirizine did not interact with antipyrine, pseudoephedrine, erythromycin, azithromycin, ketoconazole, and cimetidine. (etykieta leku Lewocetyryzyna, Interakcje z innymi lekami)

These include itraconazole, ketoconazole, posaconazole, voriconazole, the macrolide antibiotics erythromycin and clarithromycin, the ketolide antibiotic telithromycin, HIV protease inhibitors, boceprevir, telaprevir, the antidepressant nefazodone, or cobicistat-containing products. (etykieta leku Lowastatyna, Ostrzeżenia)

Drug Interactions CYP 3A4 Inhibitors (e.g., Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g., dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of… (etykieta leku Metyloergometryna, Interakcje z innymi lekami)

Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., C max and AUC). (etykieta leku Oksybutynina, Interakcje z innymi lekami)

Examples: Macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g. ketoconazole), protease inhibitors (e.g., ritonavir). (etykieta leku Olicerydyna, Interakcje z innymi lekami)

In clinical studies, patients receiving TOBI Podhaler continued to take dornase alfa, bronchodilators, inhaled corticosteroids, and macrolides. (etykieta leku Tobramycyna, Interakcje z innymi lekami)

…With Theophylline Refer to PRECAUTIONS , Drug Interactions for information regarding table. albuterol, systemic and inhaled amoxicillin ampicillin, with or without sulbactam atenolol azithromycin caffeine, dietary ingestion cefaclor co-trimoxazole (trimethoprim and sulfamethoxazole) diltiazem dirithromycin enflurane famotidine felodipine finasteride hydrocortisone… (etykieta leku Aminofilina, Interakcje z innymi lekami)

No clinically significant drug interactions with oral cetirizine hydrochloride, the active ingredient in QUZYTTIR, have been found with theophylline at a low dose, azithromycin, pseudoephedrine, ketoconazole, or erythromycin. (etykieta leku Cetyryzyna, Interakcje z innymi lekami)

Inhibitors of Cytochrome P450 3A4 In controlled clinical studies co-administration of desloratadine with ketoconazole, erythromycin, or azithromycin resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine. [See Clinical Pharmacology (12.3) .]… (etykieta leku Desloratadyna, Interakcje z innymi lekami)

…theophylline.* albuterol, systemic and inhaled mebendazole amoxicillin medroxyprogesterone ampicillin, with or without methylprednisolone sulbactam metronidazole atenolol metoprolol azithromycin nadolol caffeine, dietary ingestion nifedipine cefaclor nizatidine co-trimoxazole (trimethoprim and sulfamethoxazole) norfloxacin ofloxacin diltiazem omeprazole dirithromycin… (etykieta leku Teofilina, Interakcje z innymi lekami)